What is Synagis (palivizumab)?
Synagis is a brand name for palivizumab, a preventive medicine used to help protect certain high-risk babies from serious respiratory syncytial virus (RSV) infection [1].
Who typically gets Synagis?
Synagis is given to infants at higher risk for severe RSV disease. The exact eligibility depends on factors such as age and underlying medical conditions, and clinicians follow current guidance for RSV prevention [1].
How is Synagis given?
Synagis is administered as an injection. Dosing is scheduled during the RSV season for eligible infants, with repeat doses depending on the prescribing plan used by the care team [1].
When does Synagis work, and how long does protection last?
Synagis is intended for seasonal prevention, so babies receive doses during the period when RSV is circulating. Protection is not indefinite; it is maintained through the seasonal dosing schedule [1].
What are common side effects or risks?
Like other medicines, Synagis can cause side effects. Common concerns involve reactions around the injection site and general medication-related effects. Serious allergic reactions are possible with any injectable biologic product, so clinicians monitor for adverse reactions during and after dosing [1].
Is Synagis the same as vaccines for RSV?
No. Synagis is an antibody-based preventive medicine given to babies to reduce risk of infection during RSV season. That’s different from RSV vaccines, which work by training the immune system rather than providing immediate antibody protection [1].
Where does Synagis fit compared with other RSV prevention options?
Synagis is one RSV prevention strategy using monoclonal antibodies. Other approaches may include different monoclonal antibodies or prevention products depending on age and eligibility criteria, but Synagis remains a key option for appropriate high-risk infants under clinician guidance [1].
---
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125248